Advertisement

Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution

  • Vaia FlorouEmail author
  • Andrew E. Rosenberg
  • Eric Wieder
  • Krishna V. Komanduri
  • Despina Kolonias
  • Mohamed Uduman
  • John C. Castle
  • Jennifer S. Buell
  • Jonathan C. Trent
  • Breelyn A. Wilky
Open Access
Correction
  • 72 Downloads

Correction to: J ImmunoTher Cancer

https://doi.org/10.1186/s40425-019-0689-7

Following publication of the original article [1], the authors have reported that the following sentence “While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have enhanced activity against T regulatory cells.”

should be replaced with

“Ipilimumab and AGEN1884 are IgG1 class antibodies. AGEN1884 data show CTLA-4 inhibition and activity against T regulatory cells (reference 8).”

Reference

  1. 1.
    Florou, et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J ImmunoTher Cancer. 2019;7:213.  https://doi.org/10.1186/s40425-019-0689-7.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Vaia Florou
    • 1
    Email author
  • Andrew E. Rosenberg
    • 1
  • Eric Wieder
    • 1
  • Krishna V. Komanduri
    • 1
  • Despina Kolonias
    • 1
  • Mohamed Uduman
    • 2
  • John C. Castle
    • 2
  • Jennifer S. Buell
    • 2
  • Jonathan C. Trent
    • 1
  • Breelyn A. Wilky
    • 1
  1. 1.Department of Medicine, Division of OncologySylvester Comprehensive Cancer Center at University of Miami Miller School of MedicineMiamiUSA
  2. 2.Agenus Inc.LexingtonUSA

Personalised recommendations